Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing.

ABSTRACT:

Background

Approximately 15% of colorectal cancers (CRCs) are associated with germline mutations. There is increasing adoption of DNA-based assays for molecular residual disease (MRD) and growing evidence supporting its clinical utility, particularly for CRC by oncologists in the U.S. We assessed the uptake of germline multi-gene panel testing (MGPT) for hereditary cancer in CRC patients receiving MRD analyses in community oncology settings.

Methods

This retrospective study included 80 patients receiving care for CRC through community oncology practices who were referred for MRD testing at a commercial laboratory (January-March 2022). Clinical data, including test requisition forms, pathology reports, and clinical notes were reviewed. Documentation of tumor microsatellite in

SUBMITTER: Schrock-Kelley S 

PROVIDER: S-EPMC11442811 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature